Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
38.79
+0.65 (1.70%)
At close: Jul 2, 2026, 4:00 PM EDT
40.04
+1.25 (3.22%)
After-hours: Jul 2, 2026, 7:52 PM EDT
Immunovant Market Cap
Immunovant has a market cap or net worth of $7.96 billion as of July 2, 2026. Its market cap has increased by 204.33% in one year.
Market Cap
7.96B
Enterprise Value
7.06B
1-Year Change
204.33%
Ranking
Category
Stock Price
$38.79
Market Cap Chart
Since June 21, 2019, Immunovant's market cap has increased from $124.38M to $7.96B, an increase of 6,303.16%. That is a compound annual growth rate of 80.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 2, 2026 | 7.96B | 54.58% |
| Dec 31, 2025 | 5.15B | 41.70% |
| Dec 31, 2024 | 3.64B | -40.34% |
| Dec 29, 2023 | 6.09B | 165.79% |
| Dec 30, 2022 | 2.29B | 134.03% |
| Dec 31, 2021 | 979.80M | -78.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 21, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Halozyme Therapeutics | 9.42B |
| Kymera Therapeutics | 9.34B |
| Praxis Precision Medicines | 8.88B |
| Protagonist Therapeutics | 8.46B |
| Vaxcyte | 8.43B |
| Rhythm Pharmaceuticals | 7.82B |
| Mirum Pharmaceuticals | 7.66B |
| TG Therapeutics | 7.56B |